公开(公告)号：EP4371558A1

公开(公告)日：2024-05-22

申请号：EP22841360.5

申请日：2022-07-12

申请人： Shanghai Aurora Biotechnology Co., Ltd.

发明人： GUO, Zhen ,  XIE, Wenfeng ,  XIAO, Xiaoling ,  WANG, Tingting ,  YING, Shuhuan

IPC分类号： A61K9/22 ,  A61K31/41 ,  A61K31/216 ,  A61K9/44 ,  A61K9/36 ,  A61K47/36 ,  A61K47/38 ,  A61P9/04

CPC分类号： A61P9/04 ,  A61K9/209 ,  A61K9/50 ,  A61K31/216 ,  A61K9/20 ,  A61K47/32 ,  A61K47/10 ,  A61K47/02 ,  A61K47/12 ,  A61K9/28 ,  A61K9/2072 ,  A61K31/41 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38

摘要： A sacubitril valsartan sodium sustained-release composition, and a preparation method therefor and the use thereof. The composition is a 24-hour sustained-release drug. Dissolution of sacubitril and valsartan simultaneously satisfies the following three features: A) dissolving no more than 40% of pharmaceutical active ingredients within 2 hours; B) dissolving 20%-75% of the pharmaceutical active ingredients within 8 hours; and C) dissolving not less than 65% of the pharmaceutical active ingredients within 24 hours. Compared with common gel sustained-release dosage forms, sacubitril and valsartan in the composition can achieve synchronous sustained release; moreover, the drug release behavior is not affected by factors such as the pH of a medium environment, gastrointestinal peristalsis, and foods, the in vivo and in vitro correlation is good, gentle release within 24 hours is achieved, and the therapeutic effect is good. Compared with common immediate-release formulations, the medication frequency is reduced, the patient compliance is improved, the medication compliance is improved for people having difficulty in swallowing such as the elderly and children, it is convenient to medicate, the toxic side effects are small, and the market prospects are good.

公开(公告)号：EP4011375A1

公开(公告)日：2022-06-15

申请号：EP20850324.3

申请日：2020-08-05

申请人： Jiangsu Yahong Meditech Co., Ltd. ,  Shanghai Yahong Meditech Co., Ltd.

发明人： LIU, Jianghua ,  GUO, Yushen ,  SHEN, Shuai ,  ZHU, Wei

IPC分类号： A61K31/47 ,  A61K47/20 ,  A61K47/12 ,  A61K9/20 ,  A61K9/36 ,  A61P35/00

摘要： A pharmaceutical composition containing nitroxoline for the treatment of bladder cancer, a nitroxoline oral solid tablet, a preparation method therefor and use thereof. The pharmaceutical composition comprises nitroxoline, a filler, a disintegrating agent, a binder, and a lubricant. The lubricant is selected from one or two of sodium dodecyl sulfate and sodium stearyl fumarate. The pharmaceutical composition has a moderate dissolution rate, can avoid the burst release phenomenon, is moisture-proof and impermeable, has good stability, is secure and effective, is convenient to take, has strong patient compliance, and meets the requirements of being an oral solid tablet. The preparation method has stable production process, good reproducibility, easy mass production, and good clinical use value and social benefits.

公开(公告)号：EP4000605A2

公开(公告)日：2022-05-25

申请号：EP20839714.1

申请日：2020-07-13

申请人： DVA Farma Mexicana S.A. de C.V.

发明人： ESCORCIA RODRÍGUEZ, Francisco ,  GARCIA MONDRAGON, Maria de Lourdes ,  FLORES NAVARRETE, Ana Karen ,  ESPITIA RODRIGUEZ, José Luis

IPC分类号： A61K9/28 ,  A61K9/30 ,  A61K9/36 ,  A61K9/50

摘要： The present document discloses compositions and procedures for applying pharmaceutical tablet coatings, recognized as film coatings wherein it is possible to obtain a final product coated with brightness superior to that achievable with typical compositions. The main difference in the composition is in the inclusion of the product derived from isomaltulose, which is a mixture of 6-O-α-D-glucopyranosyl-D-mannitol dihydrate with 6-O-α-D-glucopyranosyl-D- sorbitol, known as Isomalt, combined with a variety of film-forming polymers such as ethylene glycol and polyvinyl alcohol copolymer, copovidone, polyvinyl alcohol, and cellulosic derivatives, wherein the process conditions are advantageous as it is possible to handle high concentrations of solids in their preparation and wider applying temperature ranges than normally recommended for film coatings.

公开(公告)号：EP3782621A1

公开(公告)日：2021-02-24

申请号：EP18915676.3

申请日：2018-04-16

申请人： Jiangsu Vcare Pharmatech Co., Ltd

发明人： ZHAO, Yanlei ,  ZHANG, Jianjun ,  LIU, Xuefang ,  GAO, Yuan ,  SUN, Hongbin ,  GONG, Yanchun ,  LIU, Yongqiang

IPC分类号： A61K31/4365 ,  A61K47/38 ,  A61K47/26 ,  A61K47/36 ,  A61K9/20 ,  A61K9/36 ,  A61K9/48 ,  A61P7/02

摘要： The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is pro-vided at a suitable particle size, and the D90 thereof max ) of drug absorption. Further provided by the present invention is a method for preparing an instant release pharmaceutical preparation of an anticoagulant; according to the formulation of the drug-containing particles as disclosed by the present invention, a capsule or tablet instant release preparation having excellent stability may be obtained by means of a combination of optional preparation steps.

公开(公告)号：EP3127555B1

公开(公告)日：2018-12-12

申请号：EP15772255.4

申请日：2015-03-31

申请人： Toray Industries, Inc.

发明人： TAKAKI, Suguru ,  OHTA, Kotoe ,  HORIUCHI, Yasuhide

IPC分类号： A61K47/02 ,  A61K9/36 ,  A61K47/10 ,  A61K47/26

摘要： The present invention aims to provide a coating agent which imparts gas barrier properties to a solid preparation while keeping rapid disintegration properties of the solid preparation, and a coating formed therewith, and to provide a coated solid preparation which maintains its rapid disintegration properties and gas barrier properties, and does not generate cracks in the coating under humidified conditions. The present invention provides a coating agent for a solid preparation, which coating agent contains lactose and a swelling clay, but does not contain a water-soluble polymer, wherein the weight of the swelling clay is 20 to 50% with respect to the weight of the solid content.

公开(公告)号：EP3373918A1

公开(公告)日：2018-09-19

申请号：EP15908443.3

申请日：2015-11-12

申请人： The Research Foundation for The State University of New York

发明人： HSIAO, Benjamin S. ,  CHU, Benjamin ,  SHARMA, Priyanka R.

IPC分类号： A61K9/58 ,  A61K9/36

CPC分类号： C08H8/00 ,  C08B15/04 ,  D21C9/00 ,  Y02P20/582

摘要： The present disclosure provides methods for producing carboxylated nanocelluloses. Compared with conventional methods, the methods of the present disclosure are simple and cost-effective in the production of carboxylated (or carboxy) nanocelluloses, in embodiments nanofibers and/or nanowhiskers, directly from raw biomass, including lignocellulose wood, non-wood sources, non-lignocellulose wood, lignocellulose or pure cellulose. The carboxy groups on the surface of nanocellulose thus produced can then be easily modified into functional derivatives such as amide, acetate, ether, ester, etc.

公开(公告)号：EP3251669A1

公开(公告)日：2017-12-06

申请号：EP16743267.3

申请日：2016-01-25

申请人： Daiichi Sankyo Company, Limited

发明人： TANABE, Hideaki ,  YAMADA, Mina

IPC分类号： A61K31/40 ,  A61K9/20 ,  A61K9/36 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P13/12 ,  A61P43/00

摘要： An object is to provide a solid composition of stabilized pyrrole carboxamide. A means for achieving the object is a solid composition for medical use containing (S)-1-(2-hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)pheny 1]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide and an appropriate additive.

摘要翻译： 目的是提供稳定的吡咯甲酰胺的固体组合物。 （S）-1-（2-羟乙基）-4-甲基-N- [4-（甲基磺酰基）苯基] -5- [2-（三氟甲基）苯基] 苯基] -1H-吡咯-3-甲酰胺和适当的添加剂。

公开(公告)号：EP2520183B1

公开(公告)日：2017-07-05

申请号：EP12177163.8

申请日：2006-02-03

申请人： Heger, Peter ,  Dr. Loges + Co. GmbH

发明人： Heger, Peter ,  Dr. Rettenberger, Reinhard ,  Spaich, Carl-Friedrich

IPC分类号： A23L33/105 ,  A61K9/20 ,  A61K9/32 ,  A61K9/36 ,  A61K31/085 ,  A61K31/7034 ,  A61K36/15 ,  A61K36/481 ,  A61K36/482 ,  A61K36/708 ,  A61P25/06 ,  A61P25/22 ,  A61P25/24 ,  A61P29/00

CPC分类号： A61K36/708 ,  A23L33/105 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K31/085 ,  A61K31/7034 ,  A61K36/15 ,  A61K36/481 ,  A61K36/482 ,  A61K2300/00

公开(公告)号：EP3127555A1

公开(公告)日：2017-02-08

申请号：EP15772255.4

申请日：2015-03-31

申请人： Toray Industries, Inc.

发明人： TAKAKI, Suguru ,  OHTA, Kotoe ,  HORIUCHI, Yasuhide

IPC分类号： A61K47/02 ,  A61K9/36 ,  A61K47/10 ,  A61K47/26

摘要： The present invention aims to provide a coating agent which imparts gas barrier properties to a solid preparation while keeping rapid disintegration properties of the solid preparation, and a coating formed therewith, and to provide a coated solid preparation which maintains its rapid disintegration properties and gas barrier properties, and does not generate cracks in the coating under humidified conditions. The present invention provides a coating agent for a solid preparation, which coating agent contains lactose and a swelling clay, but does not contain a water-soluble polymer, wherein the weight of the swelling clay is 20 to 50% with respect to the weight of the solid content.

摘要翻译： 本发明的目的是提供一种涂布剂，其赋予阻气性的固体制剂，同时保持固体制剂的快速崩解性，并与形成有涂层，并提供一种涂覆的固体制剂，其保持它的快速崩解性和阻气 性质，并且不产生加湿条件下的涂层裂纹。 本发明提供了一种固体制剂，该涂层剂含有乳糖和溶胀粘土的涂布剂，但不包含水溶性聚合物，worin膨润性粘土的重量为20〜50％，相对于重量 固体含量。

公开(公告)号：EP3079663A1

公开(公告)日：2016-10-19

申请号：EP14824664.8

申请日：2014-12-12

申请人： Biogen MA Inc.

发明人： ZAWANEH, Peter ,  KARKI, Shyam, B. ,  KAUFMAN, Michael ,  LEUNG, Cheuk-Yui ,  DONG, Jinquan ,  QUAN, Ernest ,  VASUDEVAN, Kalyan

IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K9/50 ,  A61K31/215 ,  A61K9/24 ,  A61K9/32 ,  A61K9/36 ,  A61K9/58 ,  A61K9/62 ,  A61P25/00

CPC分类号： A61K9/0065 ,  A61K9/0004 ,  A61K9/14 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2886 ,  A61K9/4808 ,  A61K9/5026 ,  A61K9/5031 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5073 ,  A61K31/22

摘要： A controlled release dosage form containing monomcthyl fumarate, a compound that can be metabolized into monomcthyl fumarate
in vivo , or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomcthyl fumarate, a compound that can be metabolized into monomcthyl fumarate
in vivo , or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomcthyl fumarate, a compound that can be metabolized into monomcthyl fumarate
in vivo , or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomcthyl fumarate, a compound that can be metabolized into monomethyl fumarate
in
vivo , or a pharmaceutically acceptable salt thereof or combinations thereof.

摘要翻译： 受控释放剂型含富马酸单甲酯，化合物也可被代谢成富马酸单甲酯在体内，或药学上可接受的盐或其组合，worin的富马酸单甲酯，化合物也可在体内代谢成富马酸单甲酯，或 药学上可接受的盐或其组合被递送至受试者。 如此提供的是通过口服施用的控释剂型包含富马酸单甲酯治疗的疾病或病症（例如多发性硬化）的方法，化合物也可被代谢成富马酸单甲酯在体内，或者它们或它们的组合药学上可接受的盐 ，worin的富马酸单甲酯，化合物也可被代谢成富马酸单甲酯在体内，或者它们的组合或药学上可接受的盐。